SummitTX Capital’s Amgen AMGN Stock Holding History

SummitTX Capital’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-3,749	Closed	-$1.09M	–	744
2025 Q2	$1.05M	Buy	+3,749	New	+$1.06M	0.05%	360

Other funds holding AMGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

SummitTX Capital's AMGN Position: Q3 2025 in Review

SummitTX Capital sold out of Amgen (AMGN) in Q3 2025, closing a stake of 3,749 shares — an estimated $1.09M sold.

SummitTX Capital first reported a position in AMGN in Q2 2025 and held it in 1 quarter. The position peaked at $1.05M in Q2 2025. 2,819 funds tracked by Wall St. Rank hold AMGN as of Q3 2025.

SummitTX Capital reported no remaining Amgen position as of Q3 2025 after selling out during the quarter.
SummitTX Capital sold 3,749 Amgen shares in Q3 2025, an estimated $1.09M.
SummitTX Capital first reported a position in Amgen in Q2 2025 and held it in 1 quarter.
SummitTX Capital's Amgen position peaked at $1.05M in Q2 2025.
2,819 funds tracked by Wall St. Rank held Amgen as of Q3 2025.

Based on SummitTX Capital's 13F filing for Q3 2025, filed 14 Nov 2025.